We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
Product News

New Lung Cancer Test is Now Available in Europe

Rectangle Image
Product News

New Lung Cancer Test is Now Available in Europe

Agilent Technologies has announced the commercial availability in the EU of a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with OPDIVO® (nivolumab) for patients with non-squamous NSCLC.


The diagnostic, known as PD-L1 IHC 28-8 pharmDx the maker of OPDIVO®, an immuno-oncology therapy for patients with previously treated NSCLC. PD-L1 IHC 28-8 pharmDx was used to assess PD-L1 expression in the Phase 3 CheckMate 057 trial, in which OPDIVO® demonstrated superior overall survival in patients with previously treated metastatic non-squamous NSCLC when compared to chemotherapy.


Lung cancer is the leading cause of cancer-related deaths worldwide. Historically, the one-year overall survival in the second-line treatment of NSCLC has been about 26 percent.


"Immuno-oncology is an important area within cancer treatment, and we are excited about Agilent's involvement in the potential PD-L1 IHC 28-8 pharmDx has in helping to provide information to oncologists considering OPDIVO for patients with non-squamous non-small cell lung cancer," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group.


PD-L1 IHC 28-8 pharmDx is the first and only diagnostic assay approved to assess the survival benefit associated with OPDIVO®. PD-L1 testing is not required for the use of OPDIVO®, but it may provide additional information for physicians and inform patient dialogue.


Dako is a worldwide leader in partnering with pharmaceutical companies to develop immuno histochemical-based diagnostics for cancer therapy.

Advertisement